BACKGROUND AND PURPOSE: Nitrite (NO₂⁻) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO₂⁻ in healthy volunteers and patients with stable congestive heart failure (CHF). EXPERIMENTAL APPROACH: The acute haemodynamic effects of brachial artery infusion of NO₂⁻ (0.31 to 7.8 μmol·min⁻¹) was assessed in normal subjects (n = 20) and CHF patients (n = 21). KEY RESULTS:NO₂⁻ infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO₂⁻ infusion rates which induced no changes in normal subjects (ANOVA: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO₂⁻ infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (ANOVA: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO₂⁻ infusion. Venous plasma NO₂⁻ concentrations were lower in CHF patients at baseline, and rose substantially less with NO₂⁻ infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein-bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO₂⁻ infusion. Prolonged NO₂⁻ exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro. CONCLUSIONS AND IMPLICATIONS: The findings of arterial hyper-responsiveness to infused NO₂⁻ in CHF patients, with evidence of accelerated transvascular NO₂⁻ clearance (presumably with concomitant NO release) suggests that NO₂⁻ effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO₂⁻ as a therapeutic modality in CHF.
RCT Entities:
BACKGROUND AND PURPOSE:Nitrite (NO₂⁻) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO₂⁻ in healthy volunteers and patients with stable congestive heart failure (CHF). EXPERIMENTAL APPROACH: The acute haemodynamic effects of brachial artery infusion of NO₂⁻ (0.31 to 7.8 μmol·min⁻¹) was assessed in normal subjects (n = 20) and CHFpatients (n = 21). KEY RESULTS: NO₂⁻ infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHFpatients at NO₂⁻ infusion rates which induced no changes in normal subjects (ANOVA: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO₂⁻ infusion rate in all subjects (indicating venodilation), with CHFpatients being relatively hyporesponsive compared with normal subjects (ANOVA: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO₂⁻ infusion. Venous plasma NO₂⁻ concentrations were lower in CHFpatients at baseline, and rose substantially less with NO₂⁻ infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein-bound NO concentrations were lower in CHFpatients than normal subjects at baseline. This difference was attenuated during NO₂⁻ infusion. Prolonged NO₂⁻ exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro. CONCLUSIONS AND IMPLICATIONS: The findings of arterial hyper-responsiveness to infused NO₂⁻ in CHFpatients, with evidence of accelerated transvascular NO₂⁻ clearance (presumably with concomitant NO release) suggests that NO₂⁻ effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO₂⁻ as a therapeutic modality in CHF.
Authors: J J Atherton; T D Moore; S S Lele; H L Thomson; A J Galbraith; I Belenkie; J V Tyberg; M P Frenneaux Journal: Lancet Date: 1997-06-14 Impact factor: 79.321
Authors: G Cotter; E Metzkor; E Kaluski; Z Faigenberg; R Miller; A Simovitz; O Shaham; D Marghitay; M Koren; A Blatt; Y Moshkovitz; R Zaidenstein; A Golik Journal: Lancet Date: 1998-02-07 Impact factor: 79.321
Authors: Isla S Mackenzie; Kaisa M Maki-Petaja; Carmel M McEniery; Yi Ping Bao; Sharon M Wallace; Joseph Cheriyan; Sue Monteith; Morris J Brown; Ian B Wilkinson Journal: Arterioscler Thromb Vasc Biol Date: 2005-07-28 Impact factor: 8.311
Authors: Andrew R Coggan; Seth R Broadstreet; Kiran Mahmood; Deana Mikhalkova; Michael Madigan; Indra Bole; Soo Park; Joshua L Leibowitz; Ana Kadkhodayan; Deepak P Thomas; Dakkota Thies; Linda R Peterson Journal: J Card Fail Date: 2017-09-12 Impact factor: 5.712
Authors: Angela A Glean; Scott K Ferguson; Clark T Holdsworth; Trenton D Colburn; Jennifer L Wright; Alex J Fees; Karen S Hageman; David C Poole; Timothy I Musch Journal: Am J Physiol Heart Circ Physiol Date: 2015-09-14 Impact factor: 4.733
Authors: Vinaya Mulkareddy; Susan B Racette; Andrew R Coggan; Linda R Peterson Journal: Biochim Biophys Acta Mol Basis Dis Date: 2018-09-24 Impact factor: 5.187
Authors: Trenton D Colburn; Scott K Ferguson; Clark T Holdsworth; Jesse C Craig; Timothy I Musch; David C Poole Journal: J Appl Physiol (1985) Date: 2016-10-27
Authors: Peter J Rix; Andrew Vick; Neil J Attkins; Geoffrey E Barker; Adrian W Bott; Harry Alcorn; Mark T Gladwin; Sruti Shiva; Stephen Bradley; Azra Hussaini; William L Hoye; Ed L Parsley; Hiroko Masamune Journal: Clin Pharmacokinet Date: 2015-03 Impact factor: 6.447
Authors: Sayqa Arif; Alessandra Borgognone; Erica Lai-Sze Lin; Aine G O'Sullivan; Vishal Sharma; Nigel E Drury; Ashvini Menon; Peter Nightingale; Jorge Mascaro; Robert S Bonser; John D Horowitz; Martin Feelisch; Michael P Frenneaux; Melanie Madhani Journal: Br J Pharmacol Date: 2015-04-29 Impact factor: 8.739
Authors: Julian O M Ormerod; Sayqa Arif; Majid Mukadam; Jonathan D W Evans; Roger Beadle; Bernadette O Fernandez; Robert S Bonser; Martin Feelisch; Melanie Madhani; Michael P Frenneaux Journal: Circ Heart Fail Date: 2015-04-02 Impact factor: 8.790